Herba siegesbeckiae composition and application of herba siegesbeckiae composition in preparation of medicine for preventing and treating arrhythmia caused by antitumor medicine
The problem of arrhythmia induced by anti-tumor drugs was solved through the vegetative cerebral arrhythmia composed of vegetative cerebral arrhythmia, which significantly increased the ventricular fibrillation threshold in rats, inhibited myocardial injury enzyme spectrum and decreased myocardial muscle The activity of Ca2+-ATP enzyme in tissues has achieved effective prevention and treatment of arrhythmias.
Patent Information
- Application Number
- CN202310595838.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-11-26
AI Technical Summary
Existing anti-tumor drugs such as anthracycline chemotherapy drugs often lead to arrhythmia in the treatment of tumors, and there is no effective prevention and treatment method, especially compositions composed of cypress, syrup and syrup in this application. Missing.
Provide a composition composed of saccharin, saccharin and saccharin, called saccharin composition, for the preparation of arrhythmia drugs caused by anti-tumor drugs, and prepare powders through specific decoction and concentration processes. , and is used to increase the ventricular fibrillation threshold in rats, inhibit myocardial injury enzyme spectrum and reduce Ca2+-ATP enzyme activity in myocardial tissue.
The cephala composition significantly increased the ventricular fibrillation threshold in rats after induction of the anti-tumor drug doxorubicin, reduced the occurrence of arrhythmia, inhibited the release of myocardial damage enzyme spectrum, reduced the activity of Ca2+-ATPase in myocardial tissue, and significantly reduced the Myocardial injury.
Smart Images

Figure CN119015354A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a traditional Chinese medicine composition and application thereof, in particular to a Siegesbeckia scoparia composition and application thereof in preparing a medicine for preventing and treating arrhythmia caused by anti-tumor drugs. Background Art
[0002] Cardiovascular disease and malignant tumors are non-communicable diseases with the highest mortality rate in the world. In recent years, the long-term prognosis of patients with malignant tumors has been significantly improved. Along with the extension of survival, cardiovascular complications caused by tumor treatment have become the second largest disease affecting the long-term mortality of patients after the tumor itself, which has led to the emergence of a new interdisciplinary discipline of oncology cardiology. Anthracycline chemotherapy drugs (represented by doxorubicin) are one of the most widely used anti-tumor drugs in clinical practice. While treating tumors, they can cause myocardial damage and arrhythmias, seriously affecting the survival outcomes of patients. Therefore, there is an urgent need to explore drugs to prevent and treat arrhythmias caused by chemotherapy drugs.
[0003] According to traditional Chinese medicine, arrhythmia belongs to the category of "palpitations" and "flustered palpitations", which is a syndrome of deficiency in the underlying body and excess in the superficial symptoms. The pathogenesis of arrhythmia induced by chemotherapy drugs is the retention of cold poison, obstruction of the heart meridians, and stagnation of qi and blood. The main treatment method is to dredge the meridians and activate the collaterals, and to restore the pulse and calm the palpitations.
[0004] At present, there is no report on the use of a composition composed of Siegesbeckia serrata, Periploca odorata and Nardostachys grandiflora for preparing a drug for preventing and treating arrhythmia caused by anti-tumor drugs. Summary of the invention
[0005] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a Siegesbeckia sibiricum composition.
[0006] The second object of the present invention is to provide an application of a Siegesbeckia sibiricum composition in the preparation of a drug for preventing and treating arrhythmia caused by anti-tumor drugs.
[0007] The technical solution of the present invention is summarized as follows:
[0008] The Siegesbeckia composite material is composed of Siegesbeckia herb decoction pieces, Perennial Croton Cortex decoction pieces and Nardostachys grandiflora decoction pieces.
[0009] Preferably, the mass ratio of the Siegesbeckiae decoction pieces, the Cortex Periplocae decoction pieces and the Nardostachys grandiflora decoction pieces is 3-5:1:3-5.
[0010] The application of the Siegesbeckia sibiricum composition in the preparation of drugs for preventing and treating arrhythmias caused by anti-tumor drugs.
[0011] Advantages of the present invention:
[0012] (1) Experiments have shown that the Siegesbeckia sibiricum combination can significantly increase the ventricular fibrillation threshold (VFT) of rats induced by the anti-tumor drug doxorubicin and reduce the occurrence of arrhythmias.
[0013] (2) The Xijiasong combination can significantly inhibit the release of cardiac troponin T (cTnT) and creatine kinase isoenzyme CK-MB (CK-MB) in rats with doxorubicin-induced myocardial injury, thereby alleviating myocardial injury. (3) The Xijiasong combination can significantly reduce the Ca2+ level in myocardial tissue of rats with doxorubicin-induced myocardial injury. 2+ -ATPase activity. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The effect of Siegesbeckia sibiricum combination on ventricular fibrillation threshold in rats induced by antitumor drug doxorubicin.
[0015] Figure 2 The present invention is to investigate the effect of Siegesbeckia sibiricum combination on the enzyme profiles cTnT and CK-MB in rat myocardial injury induced by the anti-tumor drug doxorubicin.
[0016] Figure 3 The effect of Siegesbeckia sibiricum composition on the Ca2+ expression in rat myocardial tissue induced by antitumor drug adriamycin 2+ -Effects on ATPase activity. DETAILED DESCRIPTION
[0017] The Siegesbeckia herba slices of each embodiment of the present invention were purchased from Beijing Jinchongguang Pharmaceutical Co., Ltd. (batch number: C5171131), the Periploca cordata slices were purchased from Beijing Shengshilong Pharmaceutical Co., Ltd. (batch number: 1812028), and the Nardostachys grandiflora slices were purchased from Beijing Xidan Pharmaceutical Co., Ltd. (batch number: 22032401). The sources of the slices of the composition of the present invention are disclosed in order to better illustrate the present invention, but the sources of the slices of the present invention are not limited.
[0018] Xijiasong combination, abbreviated as XJS; it can also be called Xijiasong prescription.
[0019] Preparation of the Siegesbeckia composite: 7.5-12.5g of Siegesbeckia herb slices, 2.5g of Perennial Croton slices and 7.5-12.5g of Nardostachys grandiflora slices are taken, mixed to obtain a mixture, and the mixture is soaked in water for 20-40min at a ratio of 8-10ml of water per 1g of the mixture, boiled at 100°C for 30min, filtered to obtain a medicinal residue and a filtrate, and water is added to the medicinal residue at a ratio of 5-7ml of water per 1g of the mixture, boiled at 100°C for 30min; filtered, the two filtrates are combined, concentrated, and dried to obtain a powdered Siegesbeckia composite.
[0020] Example 1
[0021] Preparation of the Siegesbeckia composite: take 10g of Siegesbeckia herb slices, 2.5g of Perennial Croton slices and 10g of Nardostachys grandiflora slices, mix them to obtain a mixture, add water to the mixture at a ratio of 9ml of water per 1g of the mixture, soak it for 30min, boil it at 100℃ for 30min, filter to obtain a residue and a filtrate, then add water to the residue at a ratio of 6ml of water per 1g of the mixture, boil it at 100℃ for 30min; filter, combine the two filtrates, concentrate, and dry to obtain a powdered Siegesbeckia composite.
[0022] Example 2
[0023] Preparation of the Siegesbeckia composite: take 7.5g of Siegesbeckia herb slices, 2.5g of Perennial Croton slices and 12.5g of Nardostachys grandiflora slices, mix them to obtain a mixture, add water to the mixture at a ratio of 8ml of water per 1g of the mixture, soak it for 20min, boil it at 100℃ for 30min, filter to obtain a residue and a filtrate, then add water to the residue at a ratio of 5ml of water per 1g of the mixture, boil it at 100℃ for 30min; filter, combine the two filtrates, and concentrate to obtain a powdered Siegesbeckia composite.
[0024] Example 3
[0025] Preparation of the Siegesbeckia composite: take 12.5g of Siegesbeckia herb slices, 2.5g of Perennial Croton slices and 7.5g of Nardostachys grandiflora slices, mix them to obtain a mixture, add water to the mixture at a ratio of 10ml of water to 1g of the mixture, soak it for 40min, boil it at 100℃ for 30min, filter to obtain a residue and a filtrate, then add water to the residue at a ratio of 7ml of water to 1g of the mixture, boil it at 100℃ for 30min; filter, combine the two filtrates, and concentrate to obtain a powdered Siegesbeckia composite.
[0026] Example 4
[0027] The establishment, grouping and drug administration of arrhythmia in rats induced by the anti-tumor drug doxorubicin include the following steps:
[0028] Male SD rats, 250±10 g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.; the drugs were all the Siegesbeckia sibiricum composition obtained in Example 1.
[0029] (1) Forty-eight male SD rats were randomly divided into 6 groups according to the random number table method, with 8 rats in each group.
[0030] ① Control group: no drug treatment, 1ml / 100g / d normal saline gavage once a day for 7 consecutive days, and normal saline was injected intraperitoneally on the 6th day.
[0031] ② Doxorubicin group (DOX): 1 ml / 100 g / d of normal saline was administered orally once a day for 7 consecutive days, and 15 mg / kg of doxorubicin was injected intraperitoneally on the 6th day.
[0032] ③ Low dose of Xijiasong combination (2.363 g / kg / d) + doxorubicin group (XJSL+DOX): 2.363 g / kg of Xijiasong combination was administered orally once a day for 7 consecutive days, and 15 mg / kg of doxorubicin was injected intraperitoneally on the 6th day.
[0033] ④ Medium dose of Xijiasong combination (4.726 g / kg / d) + doxorubicin group (XJSM+DOX): 4.726 g / kg of Xijiasong combination was administered orally once a day for 7 consecutive days, and 15 mg / kg of doxorubicin was injected intraperitoneally on the 6th day.
[0034] ⑤ High dose of Xijiasong combination (9.452 g / kg / d) + doxorubicin group (XJSH+DOX): Xijiasong combination 9.452 g / kg was administered orally once a day for 7 consecutive days, and doxorubicin 15 mg / kg was injected intraperitoneally on the 6th day.
[0035] ⑥ Dexrazoxane + doxorubicin group (DEX+DOX): 1 ml / 100 g / d of normal saline was administered orally once a day. On the 6th day, 150 mg / kg of dexrazoxane was injected intraperitoneally 1 hour before doxorubicin injection, and 15 mg / kg of doxorubicin was injected intraperitoneally 1 hour after doxorubicin injection.
[0036] ⑦ Detection of ventricular fibrillation threshold, myocardial injury enzyme spectrum and myocardial tissue Ca in rats 48 hours after intraperitoneal injection of doxorubicin 2+ -ATPase activity. (Control group was tested after intraperitoneal injection of normal saline).
[0037] Example 5
[0038] Effect of Siegesbeckia sibiricum combination on ventricular fibrillation threshold in rats induced by the antitumor drug doxorubicin.
[0039] Experimental Materials
[0040] Instrument: BL-420S bio-function system.
[0041] Experimental methods
[0042] Rats were anesthetized by intraperitoneal injection of sodium pentobarbital (40 mg / kg), intubated with a 16G indwelling needle, connected to a ventilator for assisted breathing, connected to the BL-420 biofunction system, started the BL-420S biofunction experimental system TM_WAVE, and selected the menu "Input Signal / Path 1 / ECG" to display the electrocardiogram waveform. The chest was opened along the fourth and fifth intercostal spaces to expose the heart, the positive pole of the stimulating electrode was hooked at the apex, and the negative pole was hooked at a distance of 3 mm from the positive pole near the heart base. The electrical stimulation conditions (rough voltage, string stimulation, string length of 10 stimulation waves, and starting intensity of 1V) were set. After the graph stabilized, electrical stimulation was started, and the ventricular fibrillation of each group of rats within 15V was recorded. The voltage value that induced ventricular fibrillation for the first time was the ventricular fibrillation threshold.
[0043] Experimental Results
[0044] The ventricular fibrillation threshold results of rats in each group are shown in Table 1.
[0045] Table 1 Ventricular fibrillation threshold VFT (V) of rats in each experimental group
[0046]
[0047] Note: * P<0.05vs Control group, # P<0.05vs DOX group, n=8.
[0048] The results in Table 1 show that compared with the Control group, the ventricular fibrillation threshold of rats in the DOX group ( Figure 1 ) was significantly reduced (P < 0.05); compared with the DOX group, different doses of the Siegesbeckia sibiricum composition of Example 1 of the present invention can increase the ventricular fibrillation threshold to different degrees, among which the high-dose group of the Siegesbeckia sibiricum composition increased the ventricular fibrillation threshold, which was statistically different from the DOX group (P < 0.05); the results show that the Siegesbeckia sibiricum composition can significantly increase the ventricular fibrillation threshold of rats after induction by the anti-tumor drug doxorubicin and reduce the occurrence of arrhythmias.
[0049] Example 6
[0050] Effect of Siegesbeckia sibiricum combination on cTnT and CK-MB enzyme profiles in rat myocardial injury induced by the antitumor drug doxorubicin.
[0051] Experimental Materials
[0052] (1) Reagents: Rat cardiac troponin T (cTnT) ELISA kit (E-WL-R0151c), rat creatine kinase isoenzyme (CK-MB) ELISA kit (E-EL-R1327c).
[0053] (2) Instruments: 37°C constant temperature and humidity chamber, microplate reader (MULTISKAN MK3, Thermo, USA).
[0054] Experimental methods
[0055] (1) Serum sample collection and processing
[0056] 48 hours after intraperitoneal injection of doxorubicin, whole blood was collected from the abdominal aorta of each group of rats using a blood collection needle, and the specimens were centrifuged at 1500 rpm for 15 minutes at 4°C within 30 minutes after collection, and the supernatant was obtained to obtain serum.
[0057] (2) ELISA operation steps
[0058] ①Take the test kit out of the refrigerated environment and equilibrate it at room temperature;
[0059] ② Take out the required microporous enzyme strips from the aluminum foil bag after equilibration at room temperature for 20 minutes;
[0060] ③ Set up standard wells, blank wells and sample wells respectively. Add 100μL of the diluted standard to the standard wells, 100μL of the standard & sample diluent to the blank wells, and 100μL of the sample to be tested to the remaining wells. Cover the ELISA plate with film and incubate at 37℃ for 90 minutes.
[0061] ④ Shake off the liquid in the wells without washing. Add 100 μL of biotinylated antibody working solution to each well, cover the ELISA plate with a film, and incubate at 37°C for 1 hour.
[0062] ⑤ Shake off the liquid in the wells and pat dry on clean absorbent paper. Add 350μL of washing solution to each well, soak for 1 minute, absorb or shake off the liquid in the ELISA plate, and pat dry. Repeat this washing step 3 times.
[0063] ⑥ Add 100 μL of enzyme conjugate working solution to each well, cover the ELISA plate with a film, and incubate at 37°C for 30 minutes.
[0064] ⑦ Shake off all the liquid in the wells and wash the plate 5 times using the same method as step 3.
[0065] ⑧Add 90 μL of substrate solution (TMB) to each well, cover the ELISA plate with a film, and incubate at 37°C in the dark for about 15 minutes.
[0066] ⑨Add 50 μL of stop solution to each well to terminate the reaction. Tip: The order of adding the stop solution should be the same as that of adding the substrate solution.
[0067] ⑩Immediately measure the optical density (OD value) of each well at a wavelength of 450 nm using an enzyme-labeled instrument.
[0068] (3) Calculation of experimental results
[0069] Use CurveExpert1.4 to draw a standard curve on the coordinate paper with the OD value of the measured standard as the horizontal coordinate and the concentration value of the standard as the vertical coordinate, and obtain the linear regression equation. Substitute the OD value of the sample into the equation to calculate the concentration of the sample.
[0070] Experimental Results
[0071] The levels of cTnT and CK-MB in the serum of rats in each group are shown in Table 2.
[0072] Table 2 The levels of cTnT and CK-MB in the serum of rats in each experimental group
[0073]
[0074] Note: * P<0.05vs Control group, # P<0.05vs DOX group, n=6.
[0075] The results in Table 2 show that compared with the Control group, the cTnT ( Figure 2 A) and CK-MB( Figure 2 B) was significantly increased (P < 0.05); compared with the DOX group, different doses of the Siegesbeckia sibiricum composition of Example 1 of the present invention can reduce the levels of cTnT and CK-MB in the serum of rats in the DOX group to varying degrees (P < 0.05); the results show that the Siegesbeckia sibiricum composition can significantly reduce the myocardial damage induced by the anti-tumor drug doxorubicin in rats.
[0076] Example 7
[0077] Effect of Siegesbeckia sibiricum combination on Ca2+ expression in rat myocardial tissue induced by antitumor drug doxorubicin 2+ -Effects on ATPase activity.
[0078] Experimental Materials
[0079] (1) Reagent: Rat Ca 2+ -ATPase colorimetric test kit (E-BC-K212-M).
[0080] (2) Instruments: 37°C constant temperature and humidity chamber, microplate reader (MULTISKAN MK3, Thermo, USA).
[0081] Experimental methods
[0082] (1) Tissue sample collection and processing
[0083] Seven days after administration, the heart tissues of the rats in each group were taken and homogenized with physiological saline (0.9% NaCl). The homogenate was centrifuged and the supernatant was taken for determination. Part of the supernatant was retained for protein concentration determination.
[0084] (2) The BCA protein quantification method was used to determine the protein concentration of tissue samples after homogenization.
[0085] (3) Ca 2+ -ATPase colorimetric assay steps
[0086] ①Before testing, equilibrate all reagents to room temperature.
[0087] ② Each bottle of reagent IV was mixed and dissolved with 5 mL of double distilled water and stored at 2-8°C for 7 days; each bottle of reagent VI was mixed and dissolved with 5 mL of double distilled water and stored at 2-8°C away from light for 7 days; each bottle of reagent VIII was added with 5 mL of double distilled water, dissolved in a 90-100°C water bath, cooled to room temperature for use, and stored at 2-8°C for 7 days.
[0088] ③ Preparation of phosphorus fixer: prepare according to the volume ratio of double distilled water: reagent six working solution: reagent seven: reagent eight working solution = 2:1:1:1. The prepared phosphorus fixer should be light yellow. If it is other colors, it should be re-prepared after eliminating phosphorus pollution factors. After preparation, avoid light, prepare as needed, and store at 2-8℃ away from light for 5 days.
[0089] ④ Preparation of 0.5mmol / L standard solution: dilute reagent 9 with double distilled water at a volume ratio of 1:19, prepare as needed, and store at 2-8℃ for 7 days.
[0090] ⑤ Incubation reaction: Non-enzyme tube: Take 170μL of reagent 1, 40μL of reagent 2, and 40μL of reagent 4 and add them to a 1.5mL EP tube; Enzyme tube: Take 170μL of reagent 1, 40μL of reagent 3, 40μL of reagent 4, and 200μL of the sample to be tested and add them to a 1.5mL EP tube. Incubate the non-enzyme tube and enzyme tube at 37℃ for 20min. Add 50μL of reagent 5 to the non-enzyme tube, mix well, and then add 200μL of the sample to be tested; add 50μL of reagent 5 to the enzyme tube. Mix the non-enzyme tube and enzyme tube separately, centrifuge at 2000×g for 10min, and take the supernatant for use.
[0091] ⑥ Color development reaction: Take 20μL of double distilled water from the blank well and add it to the corresponding enzyme-labeled well; take 20μL of 0.5mmol / L standard from the standard well and add it to the corresponding enzyme-labeled well; take 20μL of the supernatant from the non-enzyme tube from the control well and add it to the corresponding enzyme-labeled well; take 20μL of the supernatant from the enzyme tube from the assay well and add it to the corresponding enzyme-labeled well. Then add 200μL of phosphorus fixative to each enzyme-labeled well.
[0092] ⑦ Shake the plate to mix, incubate at 37℃ for 30min, and measure the OD value of each well at 660nm using an ELISA reader.
[0093] (3) Calculation of experimental results
[0094] Ca in myocardial tissue 2+-ATPase activity (calculated based on tissue protein): Definition: At 37°C, the ability of ATPase in each gram of tissue protein to decompose ATP and produce 1 mmol of inorganic phosphorus per hour is defined as one unit of enzyme activity. 2+ -ATPase activity (U / gprot) = A2 / A1×C÷t×V1 / V2÷Cpr×f.
[0095] A2: OD value of the test well - OD value of the control well; A1: OD value of the standard well - OD value of the blank well; C: concentration of the standard (0.5mmol / L); t: time of the enzymatic reaction (20min=1 / 3h); V1: total volume of the incubation reaction (0.5mL); V2: volume of the sample to be tested (0.2mL); V3: volume of the homogenization medium physiological saline (mL); m: tissue weight (g); Cpr: tissue protein concentration (gprot / L); f: dilution factor of the sample before adding it to the detection system.
[0096] Experimental Results
[0097] The Ca content in myocardial tissue of rats in each group 2+ -ATPase activities are shown in Table 3.
[0098] Table 3 Ca in myocardial tissue of rats in each experimental group 2+ -ATPase activity
[0099]
[0100] Note: * P<0.05vs Control group, # P<0.05vs DOX group, n=4.
[0101] The results in Table 3 show that compared with the Control group, the myocardial Ca in the DOX group was 2+ -ATPase activity was significantly increased (P < 0.05); compared with the DOX group, different doses of the Siegesbeckia sibiricum composition of Example 1 of the present invention can reduce the Ca2+ level in the myocardial tissue of rats in the DOX group to varying degrees. 2+ -ATPase activity (P < 0.05); The results showed that the effect of the Xijiasong combination on alleviating doxorubicin-induced arrhythmia was related to its regulation of Ca in myocardial tissue. 2+ -ATPase activity.
[0102] Experiments have shown that the Siegesbeckia sibiricum composition prepared in Examples 2 and 3 improves the ventricular fibrillation threshold (VFT) of rats induced by the anti-tumor drug doxorubicin, inhibits the release of cardiac troponin T (cTnT) and creatine kinase isoenzyme CK-MB (CK-MB) in rats with myocardial injury, and reduces the Ca2+ level in myocardial tissue of rats with doxorubicin. 2+ -ATPase activity was similar to that of the Siegesbeckia sibiricum composition prepared in Example 1.
Claims
1. A Siegesbeckia sibiricum composition, characterized in that It is composed of decoction pieces of Siegesbeckia sibiricum, Cortex Periplocae and Nardostachys grandiflora.
2. The composition according to claim 1, characterized in that The mass ratio of the Siegesbeckia herb slices, the Cortex Periplocae slices and the Nardostachys grandiflora slices is 3-5:1:3-5.
3. Use of the Siegesbeckia sibiricum composition according to claim 1 or 2 in the preparation of a drug for preventing and treating arrhythmias caused by anti-tumor drugs.
Citation Information
Patent Citations
Application of herba siegesbeckiae aqueous extract in preparation of medicine for improving myocardial reperfusion injury
CN115969892A
Cited By
Herba siegesbeckiae composition and application of herba siegesbeckiae composition in preparing medicine for preventing and treating tumor heart disease
CN119015369A
